Abstract. The aim of this work is to set an adequate discrete HIV models taking into consideration two antiretroviral: Protease Inhibitors and Reverse Transcriptase Inhibitors. Furthermore, we investigate optimal control strategies in order to reduce infected cells and infectious virions. Using an iterative method, three numerical simulations are carried out, compared and interpreted to confirm the the proposed model and to prove the performance of the optimization strategies. Finally, we improve the patients' lives by minimizing serious side effects and also reducing drug costs and duration of treatments.
Introduction
HIV (human immunodeficiency virus) is the virus that causes AIDS (acquired immunodeficiency syndrome). HIV kills and damages cells of the body's immune system and destroys progressively the body's ability to fight infections and certain cancers. AIDS appeared for the first times in 80-81 years in the United States. A few years later (in 1983), HIV was highlighted at the Pasteur Institute in Paris and recognized as responsible for this syndrome. Today, over 36 million people living with HIV in the world. The latest statistics of 2014 are detailed in Table 1 , according to the World Health Organization (WHO). The immune system is a complex set of organs, cells and molecules. It is responsible for the body's defenses against infectious agents. The main components of the immune system to which we will interest are CD 4 + T lymphocytes.
We are interested in mathematical models considering the dynamic contribution of these cells.
CD4 T-cells (or T4), also known as helper T cells (Th) or
Helper T, are the cells responsible for the coordination and activation of the immune response. These cells are also produced by the thymus and have CD4 protein on their membranes. These helper cells, as their name suggests, are the key to the immune system. They help to trigger the reaction and the immune response in case of infection. The different classes of ART (antiretroviral) used against HIV act at different stages of the virus life cycle. The most common antiretroviral are mainly:
 Reverse Transcriptase Inhibitors (RTIs);  Protease Inhibitors (PIs). Unfortunately, much of infected does not receive ART, especially in countries whose income is low or limited. The Table 2 , according to the World Health Organization (WHO), shows clearly this reality. Mathematical modeling of biological processes aims to better understand complex or often misunderstood phenomena of these bio-processes. A mathematical model is a set of mathematical equations that links; on one side, a set of variables which are states of the system studied for example body temperature, viral load, on the other hand, a set of parameters that are constants or variables specific to the system, for example the mass body, the life of the virus. In addition, the mathematical model takes also into consideration a set of constraints.
In this study, we adopt discrete-time models for many reasons: the statistics data concerning HIV infection are collected in discrete-time, the discrete-time models may escape some mathematical complexities like regularity of solutions, adequate topology and the choice of state space. [3] introduced chemotherapy in an early treatment setting and used a single control, the results don't depend on the treatment duration. This paper is organized as follows. In the next section, we develop several HIV models until getting the discrete HIV models with two classes of antiretroviral (RTIs) and (PIs). In section 3, the analysis of optimization problem is presented. In section 4, we suggest a numerical appropriate method and the corresponding simulation results. Finally, conclusions are summarized in the last section.
Presentation of Discrete HIV Model with Two Controls
In this section, different HIV models will be described, explained, discussed and presented. In fact, we show different steps traversed in order to reach the final model this our subject matter.
Discrete HIV Model
In this subsection, we present a discrete HIV model under therapy. The model takes into consideration three variable states described below. uninfected CD4 + T-cells at time k;
infected CD4 + T-cells cells at time k;
infectious virus at time k.
Uninfected CD4 + T-cells are produced at a rate s and cleared at a rate d. Infectious virus die at a rate µ and infected CD4 + T-cells die at a rate a. The movement from class of uninfected cells to class of infected cells is described by , where is the effective contact rate. Hence, the term is subtracted from uninfected CD4 + T-cells and added to infected cells . The virus is produced by infected cells at a rate K . Furthermore, through therapy a part of infected cells may also revert to the uninfected state by loss of all cccDNA from their nucleus at a rate r. Hence, the model is described as follows (1) 
Discrete HIV model with Protease Inhibitors (PIs)
Protease Inhibitors (PIs) are kind of medications used to treat or prevent infection by viruses, in other words, they work by blocking the activity of reverse transcriptase and prevent production of viruses from the actively infected CD4 + T-cells, see table 3. 
The Optimal Control Problem
In this section, our target is to minimize the objective functional defined in (6) by decreasing the number of infected cells and the number of infectious virus. On top of that, we are interested also in reducing costs of treatment by Protease Inhibitors (PIs) and Reverse Transcriptase Inhibitors (RTIs). We first define as the objective functional given by (6) For simplicity the cost of each treatment is considered quadratic, where A, C, B 1 , and B 2 are the cost coefficients and depend respectively on the relative importance of , ,
, and .
The positive constants A, C, B 1 , and B 2 represent desired weight on the benefit and cost, and are bounded, lebesgue integrals functions and reflect the severity of the side effects of the drugs [2] . We are looking for optimal control which verifies (7)
Existence of an optimal control
The existence of the optimal control pair can be obtained using a result by Fleming and Rishel [4] and by Lukes [5] .
Theorem 3.1 There exists control function which verifies

Proof
To prove the existence of an optimal control pair it is sufficient to verify that 1) The set of controls and corresponding state variables is nonempty.
2) The admissible set is convex and closed.
3) The right hand side of the state system (5) The result follows directly from (Fleming and Rishel 1975) . In order to verify these conditions, we use a result by Lukes [5] to give the existence of solutions of (5) with bounded coefficients, which gives condition 1. We note that the solutions are bounded. Our control set satisfies condition 2. Since our state system is bilinear in and , the model (5) satisfies condition 3, using the boundedness of the solutions. Note that the integrand of our objective functional is concave. Also we have the last condition needed where c 2 depends on the upper bound on y and v, furthermore c 1 > 0 since B 1 , B 2 > 0. We conclude there exists an optimal control pair.
Characterization of the Optimal Control
According to the Pontryagin's Maximum Principal in discrete-time, Equations (5), (6) and (7) will be converted into a problem of minimizing a Hamiltonian . At each time step k, the Hamiltonian is given by (8) 
Proof.
The Hamiltonian is given by (11) According to the Pontryagin's Maximum Principle in discrete time, see [6] , the equations for the adjoint variables, for k=0,1..,T−1, are
For k=0,1..,T−1, the control characterization is derived from (13) Subject to the lower and upper bounds for , the characterization becomes
Implementation and interpretation
In this section, we make use of an iterative method with forward solving of the state system followed by backward solving of the adjoint system and we give the meaning and the estimated value of each parameter in table 5. Also, we present three numerical illustrations using different weight factors. In each example, we achieve relevant results that help us to compare between before and after of these treatments namely the uninfected cells, the infected cells and the viral load.
Numerical method and estimated parameters
In this study, we will implement numerical method for solving this problem. This system consists of the state system, adjoint system, initial and final time conditions, and the controls characterization. The optimality system is given by (14) With these initial conditions and the transversality conditions are given by There are initial conditions for the state variables and terminal conditions for the adjoints. That is, the optimality system is a two-point boundary value problem, with separated boundary conditions at times step k = 0 and k = T . We solve the optimality system by an iterative method with forward solving of the state system followed by backward solving of the adjoint system. We start with an initial guess for the controls at the first iteration and then before the next iteration, we update the controls via the characterization [7] . We exploit several resources [8] , [9] , [10] , [11] , [12] , [13] in order to extract the different estimated parameters. So, a complete list of parameters and their estimated values are given in table 5 . Chemotherapy has potentially hazardous side effects. Therefore, the length of treatment is restricted. For most HIV chemotherapy drugs, the length of treatment is less than 500 days. In addition, the optimal controls will depend implicitly on the length of the treatment, and the general shape of the optimal controls stays the same as the treatment interval changes [14] . Hence, the period of the therapy considered at the first is 100 days.
In the following simulations, we adopt initial conditions given by: =1000cell.mm −3 , =100cell.mm −3 , =30vir.mm −3 and =0vir.mm −3 .
Numerical Illustration 1
In the first illustration, the weight factors are given by: A = 20, B 1 = 3000, B 2 = 2000 and C = 500. The figure 1 gives us the opportunity to compare easily the behaviors of the two discrete HIV models, before and after therapy with Protease Inhibitors (PIs) and Reverse Transcriptase Inhibitors (RTIs). In addition to this, optimal chemotherapy strategy for the HIV infection is viewed on the figure 2. On the whole, we can deduce that introduction of therapy by Protease Inhibitors (PIs) and Reverse Transcriptase Inhibitors (RTIs) has a powerful rule to fight HIV infection and improve the life of the patient. These beneficial results are obtained by the treatment described in Fig.2 . The first control has a duration of 75 days, whereas the second control has duration of 80 days. Hence, the treatment lasts 80 days.
Numerical Illustration 2
In the second illustration, the weight factors are given by: A = 1000, B 1 = 500, B 2 = 1000 and C = 200. Evolution of cells and virus is described clearly in the Fig.3 which permits us to confirm that treatment is able to reduce more and more concentration of infected cells and infectious virus. Despite changing weight factors, the result related to concentration of uninfected cells, infected cells, infectious virus and noninfectious virus differ but slightly, in other words Fig.3 don't bring an extra supply. Unlike optimal controls, adopted in this second simulation, are different to optimal controls in the first simulation, see Fig.2 and Fig.4 , whereas the treatment here has the same duration 80 days.
Numerical Illustration 3
In the last illustration, the weight factors are given by: A = 3000, B 1 = 50, B 2 = 10 and C = 400. In this subsection, we vary the weight factors once more, but evolution of uninfected cells, infected cells, infectious virus and noninfectious virus is almost the same compared to the first simulation, see Fig.1 and Fig.5 . According to Fig.6 , the first control has a duration of 75 days, whereas the second control has duration of 92 days. Consequently, the treatment requires a longer period 92 days.
Conclusion
This research is part of a multidisciplinary subject and its objective was to study mathematical modeling and optimal control of HIV/AIDS infection. Our approach consists of modeling in discrete time dynamics evolution of the infection, mainly the dynamics of viral load in order to predict its evolution and adopt a medical and economic strategy in a relevant and efficient way. Despite these many scientific advances due in particular to chemical engineering, genetic engineering and biomedical, HIV/AIDS remains a major scientific problem. Antiretroviral (ART) that exist allow to lower the viral load in the patient in order to slow the depletion of the immune system but eradication of virus from the body is still impossible. In addition to the high costs of these ART, treatments are very heavy for the patient considering their severe side effects (neurological disorders, acute diarrhea, metabolic disorders, etc.) and often irreversible [8] , [15] . To evaluate this work and to establish better treatment strategy, we have investigated three different numerical simulations and have achieved many objectives and results. First, the treatment period was reduced to 92 days in the worst case. Second, without controls, infected cells and viral load decrease at a slower rate than in case of control with two therapies (PIs) and (RTIs). These latest results confirm the effectiveness of the optimal control in terms of time and in terms of improvement of the health of patients. To end, another point to raise is that despite the change of weight factors in each illustration, the results at the patient's health are beneficial and almost identical, while the treatment varied from one case to another in terms of distribution and duration. The purpose of this work is to offer intelligent tools that will serve the field of biomedicine and can help the public health authorities to intervene in the right time and with the right way. Not to mention that, according to results approved in this research, governmental organizations, non-governmental organizations and the international community should react as soon as possible to provide ART especially in low and middle income countries to preserve the life of humanity. 
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